These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 23401433)

  • 1. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.
    Li T; Kung HJ; Mack PC; Gandara DR
    J Clin Oncol; 2013 Mar; 31(8):1039-49. PubMed ID: 23401433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
    Gutierrez ME; Choi K; Lanman RB; Licitra EJ; Skrzypczak SM; Pe Benito R; Wu T; Arunajadai S; Kaur S; Harper H; Pecora AL; Schultz EV; Goldberg SL
    Clin Lung Cancer; 2017 Nov; 18(6):651-659. PubMed ID: 28479369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.
    Fumagalli C; Vacirca D; Rappa A; Passaro A; Guarize J; Rafaniello Raviele P; de Marinis F; Spaggiari L; Casadio C; Viale G; Barberis M; Guerini-Rocco E
    J Clin Pathol; 2018 Sep; 71(9):767-773. PubMed ID: 29535211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.
    Faber E; Grosu H; Sabir S; San Lucas FA; Barkoh BA; Bassett RL; Luthra R; Stewart J; Roy-Chowdhuri S
    J Clin Pathol; 2022 Sep; 75(9):612-619. PubMed ID: 33952592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
    Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
    J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalizing therapy in advanced non-small cell lung cancer.
    Villaruz LC; Burns TF; Ramfidis VS; Socinski MA
    Semin Respir Crit Care Med; 2013 Dec; 34(6):822-36. PubMed ID: 24258572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
    Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
    Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.
    Gray J; Thompson JC; Carpenter EL; Elkhouly E; Aggarwal C
    Oncologist; 2021 Oct; 26(10):e1812-e1821. PubMed ID: 34216176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing.
    Prabhash K; Advani SH; Batra U; Biswas B; Chougule A; Ghosh M; Muddu VK; Sahoo TP; Vaid AK
    Adv Ther; 2019 Apr; 36(4):766-785. PubMed ID: 30864106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
    Remon J; Pignataro D; Novello S; Passiglia F
    Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice.
    Moore DA; Balbi K; Ingham A; Arkenau HT; Bennett P
    J Clin Pathol; 2018 Nov; 71(11):1001-1006. PubMed ID: 30054375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
    Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
    Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting.
    Presley CJ; Tang D; Soulos PR; Chiang AC; Longtine JA; Adelson KB; Herbst RS; Zhu W; Nussbaum NC; Sorg RA; Agarwala V; Abernethy AP; Gross CP
    JAMA; 2018 Aug; 320(5):469-477. PubMed ID: 30088010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
    Aggarwal C; Thompson JC; Black TA; Katz SI; Fan R; Yee SS; Chien AL; Evans TL; Bauml JM; Alley EW; Ciunci CA; Berman AT; Cohen RB; Lieberman DB; Majmundar KS; Savitch SL; Morrissette JJD; Hwang WT; Elenitoba-Johnson KSJ; Langer CJ; Carpenter EL
    JAMA Oncol; 2019 Feb; 5(2):173-180. PubMed ID: 30325992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
    Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.